Nurosym Announces Non-Invasive Vagus Nerve Stimulator For UK-Wide Distribution

Parasym expands its UK-wide distribution of Nurosym, a CE-marked vagus nerve stimulation wearable using AVNT™ technology.

London, United Kingdom, October 12, 2026 -- Parasym has announced the UK-wide distribution of Nurosym, its CE-marked wearable vagus nerve stimulation device. The news comes as the company broadens the reach of a non-invasive neuromodulation option for those seeking quality of life improvements and health support beyond conventional care routes.

More information is available at: https://nurosym.com/en-gb/products/nurosym

Nurosym is backed by more than 60 completed clinical studies, with research partnerships extending to institutions from Harvard and UCLA to Bart’s Health NHS Trust and the University of Chicago Medical School. Those studies have combined to find a wide variety of encouraging outcomes among participants spanning reduced fatigue (average fall of 48%) to heightened vagus nerve activity (average rise of 61%).

This ties into one of Nurosym’s sole aims - which Parasym's Head of Science, Greta Dalle Luche, PhD, largely describes in terms of restoration:

“The nervous system and one of its largest nerves - the vagus nerve - controls critical bodily functions, from breathing, heart rate, and digestion to energy management, calmness, and mood. When the vagus nerve is not functioning properly, symptoms can surface that relate to these processes (e.g., chronic tiredness or chronic stress). By signalling the nervous system in a natural way through modulating the activity of the vagus nerve, Nurosym helps to bring the body back to its healthy state and maintain it in balance.”

Such results remain sought after by those living with conditions such as chronic fatigue, stress, or symptoms stemming from the pandemic - many of whom may have already tried numerous approaches without lasting relief. While Nurosym notably isn’t positioned as a replacement for traditional medical treatment, Dr. Dalle Luche highlights its suitability as a non-drug option designed to support the nervous system alongside existing care.

This is a potentially vital distinction for those who’ve often felt dismissed when conventional medicine failed to resolve their symptoms, with Nurosym representing an alternative treatment to be used at home. Dr. Dalle Luche refers to the device as a small wearable VNS device with an earpiece that clips onto the tragus - in other words, where the outer ear meets the ear canal and where the vagus nerve reaches the skin.

Through this point, Nurosym is said to deliver gentle electrical pulses using AVNT™, Parasym's proprietary waveform. The vagus nerve carries signals between the brain and organs such as the heart, lungs, and gut, and, according to Dr Dalle Luche, this in turn plays a crucial role in how the body manages stress, rest, and recovery.

About Nurosym

Parasym states that its AVNT™ technology is among the most studied and peer-reviewed transcutaneous auricular vagus nerve stimulation (taVNS) systems available, supported by more than 60 completed clinical studies conducted in partnership with institutions including Harvard, UCLA, and Bart's Health NHS Trust. Nurosym's US equivalent, Nuropod, has also received recognition in the United States market.

Additional details are available at: https://nurosym.com/

*Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as medical claims or guaranteed individual outcomes. Nurosym is a CE-marked medical device in Europe.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nurosym by Parasym
Address: 18 Saint Cross Street 4th Floor, London, England EC1N 8UN, United Kingdom
Website: https://nurosym.com/

Release ID: 89205840

If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.

You May Also Be Interested In

• Rob Spampinato Reshapes the Music Education Landscape
• LavishCars Expands into the United States with Houston Marketplace Launch
• DuLac Farmaceutici Takes Next Step in U.S. Retail Growth Following ECRM Meetings